Skip to content
Triangle logo TriangleGet started
← Study library

NCT01154452 · REGISTRY CONDITION SEARCH

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2018-08-15

This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must have histologically or cytologically confirmed sarcoma * All Patients must have measurable disease as defined by RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * There is a minimum of 1 prior therapy; however, there are no minimum systemic therapy requirements for well differentiated or de-differentiated liposarcoma, clear cell sarcoma, chondrosarcoma, alveolar soft part sarcoma and chordomas which have no effective therapies; for Phase Ib, there are no maximum limits to number of prior therapies; for Phase II, there is a maximum of 5 prior chemotherapy regimens including tyrosine kinase inhibitors (TKI); the last dose of systemic therapy (including TKI) must have been given at least 2 weeks prior to initiation of therapy; patients receiving nitrosourea (such as BCNU) or mitomycin C must have received their last dose of such therapy at least 6 weeks prior to initiation of therapy; patients receiving bevacizumab must wait at least 4 weeks; patients receiving experimental immunotherapy or antibody based therapies must wait a minimum of 4 weeks or 4 half-lives, whichever is longer; this should be discussed with the principal investigator before registration; tumor biopsies should be performed only after meeting these requirements; patients should recover to less than Common Terminology Criteria for Adverse Events (CTCAE) grade 2 toxicities related to previous therapies to be eligible * Patients with metastatic or locally advanced (inoperable) gastrointestinal stromal tumor (GIST) must have progressed on imatinib and sunitinib or be intolerant to both drugs; the last dose of tyrosine kinase inhibitors imatinib or sunitinib should be given at least 2 weeks prior to initiation of therapy * Patients with brain metastasis that have been treated with definitive surgery or radiation and have been clinically stable for 3 months following the procedure with no neurological signs or symptoms and no requirement for systemic glucocorticoids are eligible for study * Patients must not have current evidence of another malignancy except non-melanoma skin cancer and superficial bladder cancer * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Hemoglobin \>= 9 g/dl * Platelets \>= 100,000/mcL * Total bilirubin =\< upper limit of normal * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 X upper limit of normal * Creatinine =\< 1.5 or creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above 1.5 * Patients treated at Memorial Sloan-Kettering Cancer Center may consent to optional tumor biopsies before and after initiation of study drug; tumor biopsies should be obtained after fulfilling requirements * Women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 12 months post-treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; women of childbearing potential are required to have a negative pregnancy test (with a sensitivity of at least 25 mIU/mL) within 7 days and within 24 hours prior to the first dose of GDC-0449 and/or RO4929097 (serum or urine); a pregnancy test (serum or urine) will be administered every 3 weeks to all women of childbearing potential, at the start of each drug cycle; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449 and/or RO4929097, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm that patient understands the teratogenic potential of GDC-0449 and/or RO4929097 * Female patients of childbearing potential are defined as follows: * Patients with regular menses * Patients, after menarche with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding * Women who have had tubal ligation * Female patients may be considered to NOT be of childbearing potential for the following reasons: * The patient has undergone total abdominal hysterectomy with bilateral salpingo-oophorectomy or bilateral oophorectomy * The patient is medically confirmed to be menopausal (no menstrual period) for 24 consecutive months. * The patient is post-menopausal defined by amenorrhea for at least 1 year in a woman \> 45 years old * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients may not receive other investigational agents within 2 weeks of enrollment in this study; patients treated with bevacizumab should be off therapy for 4 weeks; other experimental or immuno therapies should wait for 4 half-lives or 4 weeks, whichever is longer; prior exposure to Notch or Hedgehog inhibitors is not allowed; patients who have not recovered to less than CTCAE grade 2 from prior therapies are ineligible * History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449 or RO4929097 used in the study * Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®) are ineligible; patients on warfarin may be considered for enrollment after cessation of warfarin and appropriate transition to alternate anti-coagulation agents * Preclinical studies indicate that RO4929097 is a substrate of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) and inducer of CYP3A4 enzyme activity; caution should be exercised when dosing RO4929097 concurrently with CYP3A4 substrates, inducers, and/or inhibitors; furthermore, patients who are taking concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4 should be switched to alternative medications to minimize any potential risk; the following medications with strong potential for interaction are not allowed: indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone * Caution should be exercised when dosing GDC-0449 concurrently with medications that are substrates of cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8), CYP2C9, and CYP2C19 and have narrow therapeutic windows; caution should be exercised when dosing GDC-0449 concurrently with inhibitors of CYP3A4 * Patients must be able to swallow pills; patients with malabsorption syndrome or other condition that would interfere with intestinal absorption * Patients with clinically active liver disease, including active viral or other hepatitis or cirrhosis, are ineligible * Patients with uncontrolled electrolyte abnormalities including hypophosphatemia, hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia or defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, a history of torsades de pointes or other significant cardiac arrhythmias that require antiarrhythmics or other medications known to prolong corrected QT interval (QTc); psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449 and/or RO4929097 * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible * Cardiovascular: baseline QTc \> 450 msec (male) or QTc \> 470 msec (female)
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
    intervention Names
    1. Drug: Gamma-Secretase Inhibitor RO4929097
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    label
    Arm I (gamma-secretase inhibitor RO4929097)
    type
    EXPERIMENTAL
  2. description
    Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
    intervention Names
    1. Drug: Gamma-Secretase Inhibitor RO4929097
    2. Other: Laboratory Biomarker Analysis
    3. Other: Pharmacological Study
    4. Drug: Vismodegib
    label
    Arm II (vismodegib and gamma-secretase inhibitor RO4929097)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Arm I (gamma-secretase inhibitor RO4929097)
    2. Arm II (vismodegib and gamma-secretase inhibitor RO4929097)
    description
    Given PO
    name
    Gamma-Secretase Inhibitor RO4929097
    other Names
    1. RO4929097
    type
    DRUG
  2. arm Group Labels
    1. Arm I (gamma-secretase inhibitor RO4929097)
    2. Arm II (vismodegib and gamma-secretase inhibitor RO4929097)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  3. arm Group Labels
    1. Arm I (gamma-secretase inhibitor RO4929097)
    2. Arm II (vismodegib and gamma-secretase inhibitor RO4929097)
    description
    Correlative studies
    name
    Pharmacological Study
    type
    OTHER
  4. arm Group Labels
    1. Arm II (vismodegib and gamma-secretase inhibitor RO4929097)
    description
    Given PO
    name
    Vismodegib
    other Names
    1. Erivedge
    2. GDC-0449
    3. Hedgehog Antagonist GDC-0449
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
78
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Maximum-tolerated Dose of Gamma-secretase Inhibitor RO4929097, Defined as the Dose Level Where no More Than 1 Out of 6 Patients Experience DLT at the Highest Dose Level Below the MAD, Graded According to NCI-CTCAE Version 4.0 (Phase Ib)
    time Frame
    Up to 28 days
  2. description
    Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)
    measure
    Progression-free Survival (PFS)
    time Frame
    6 weeks
secondary Outcomes
  1. description
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
    measure
    Response Rate (CR + PR) as Assessed by RECIST 1.1 (Phase Ib and II)
    time Frame
    Up to 4 months
Full study description
brief Summary
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.
detailed Description
PRIMARY OBJECTIVES: I. To determine the maximum-tolerated dose (MTD) of gamma-secretase inhibitor RO4929097 (RO4929097) when given in combination with fixed-dose Hedgehog antagonist GDC-0449 (GDC-0449) which will become the recommended dose for the phase II portion of this study. (Phase Ib) II. To assess the progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in two arms of patients with advanced sarcoma. (Phase II) SECONDARY OBJECTIVES: I. To describe the tolerability and adverse event profile of daily GDC-0449 administered orally in combination with daily RO4929097 administered orally for 21 consecutive days. (Phase Ib) II. To describe the pharmacokinetics of the combination of the combination of GDC-0449 and RO4929097. (Phase Ib) III. To assess Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 overall response rates (complete and partial response \[CR+PR\]) for combination therapy. (Phase Ib and II) IV. To conduct pharmacodynamic studies in tissue biopsies (pre- and post-study) for explorative and hypothesis-generating studies. (Phase Ib and II) V. To assess overall survival. (Phase II) VI. To further describe the pharmacokinetics and pharmacodynamics of the combination of GDC-0449 and RO4929097 at the phase II dose at the continuous schedule. (Phase II) V. To conduct pharmacodynamic studies in tissue biopsies (pre- and post- study drug\[s\]) for explorative and hypothesis generating studies. (Phase II) OUTLINE: This is a phase I, dose-escalation study of gamma-secretase/notch signalling pathway inhibitor RO4929097 followed by a phase II study. PHASE IB: PART A: Patients receive vismodegib orally (PO) once daily (QD) on days 1-21. PART B: Beginning within 7 days of finishing part A, patients receive vismodegib PO and gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. PHASE II: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. ARM II: Patients receive vismodegib PO and gamma-secretase/notch signalling pathway inhibitor RO4929097 PO QD on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5a5c4008a5defaddd880
      requested nct id
      NCT01154452
      primary nct id
      NCT01154452
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      85d525294dce22130c9cf4e839b6baff6f238885e24c2c91534e7f76db68f961
      payload sha256
      cbce6774482d3e1ac1df582d27c59a56f686832fa97e17197446283e0e71170b
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5a5c4008a5defaddd880
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01154452
      occurrences
      1. context exact
        NCT01154452
        end
        11
        exact text
        NCT01154452
        start
        0
      offset unit
      unicode_code_points
      query cond
      Undifferentiated Pleomorphic Sarcoma of Bone
      query disease state id
      ds-undifferentiated-pleomorphic-sarcoma-of-bone
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-undifferentiated-pleomorphic-sarcoma-of-bone-000.json
      source file sha256
      85d525294dce22130c9cf4e839b6baff6f238885e24c2c91534e7f76db68f961
      source json pointer
      /studies/4/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a83efe883f4ef64b56d5cb90400bc0e82385f35d2a195c44e9fc55e6d92ed29b
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-60078b8e6c950689bf24
      requested nct id
      NCT01154452
      primary nct id
      NCT01154452
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      payload sha256
      5c0ce6b411ca68c6eafb9dddf6d128e582982d08cca0e1c85c479d6785804892
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-60078b8e6c950689bf24
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01154452
      occurrences
      1. context exact
        NCT01154452
        end
        11
        exact text
        NCT01154452
        start
        0
      offset unit
      unicode_code_points
      query cond
      Ovarian Germ Cell Tumors
      query disease state id
      ds-ovarian-germ-cell-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-ovarian-germ-cell-tumors-000.json
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      source json pointer
      /studies/56/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a83efe883f4ef64b56d5cb90400bc0e82385f35d2a195c44e9fc55e6d92ed29b
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-94b85985ecdf7cbc3e20
      requested nct id
      NCT01154452
      primary nct id
      NCT01154452
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      payload sha256
      d783442c8164d4199508b996d02c7989cff312ad2f09fdc57f547aba8c3873bc
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-94b85985ecdf7cbc3e20
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01154452
      occurrences
      1. context exact
        NCT01154452
        end
        11
        exact text
        NCT01154452
        start
        0
      offset unit
      unicode_code_points
      query cond
      Small Intestine Cancer
      query disease state id
      ds-small-intestine-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      source json pointer
      /studies/75/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a83efe883f4ef64b56d5cb90400bc0e82385f35d2a195c44e9fc55e6d92ed29b
    4. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-d58fa2bad91b3abfc189
      requested nct id
      NCT01154452
      primary nct id
      NCT01154452
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
      payload sha256
      1767c3d8e213757944896891ff3b67470030cda93dbfbb5014863a3dc5ba1121
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-d58fa2bad91b3abfc189
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01154452
      occurrences
      1. context exact
        NCT01154452
        end
        11
        exact text
        NCT01154452
        start
        0
      offset unit
      unicode_code_points
      query cond
      Histiocytoma
      query disease state id
      ds-histiocytoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-histiocytoma-000.json
      source file sha256
      bac1ec1281373ee4e9e39781fe34b553efe52105d6d2ce39d01500a3a6db7b66
      source json pointer
      /studies/16/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a83efe883f4ef64b56d5cb90400bc0e82385f35d2a195c44e9fc55e6d92ed29b
    5. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-db987550c8fd1eb058db
      requested nct id
      NCT01154452
      primary nct id
      NCT01154452
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      21b84c01b125d04528c86b8a2e80343ce07b200dcda51c3b1328a536daf43d89
      payload sha256
      2cfde96cdf694bebb8a088ca75302a1b31129fa20edbb65af8d89e38195d10c8
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-db987550c8fd1eb058db
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01154452
      occurrences
      1. context exact
        NCT01154452
        end
        11
        exact text
        NCT01154452
        start
        0
      offset unit
      unicode_code_points
      query cond
      Uterine Sarcoma
      query disease state id
      ds-uterine-sarcoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-uterine-sarcoma-000.json
      source file sha256
      21b84c01b125d04528c86b8a2e80343ce07b200dcda51c3b1328a536daf43d89
      source json pointer
      /studies/36/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      a83efe883f4ef64b56d5cb90400bc0e82385f35d2a195c44e9fc55e6d92ed29b

    Preserved source evidence · Not medical advice